Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for secondary cardiovascular prevention after ischemic stroke or TIA with persistent inflammation
ACTRN12621001408875Phase 3Recruiting
- Sponsor
- University of Sydney
- Start
- Mar 2023
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in atherosclerosis, ischemic stroke and transient ischaemic attack (TIA) comparing Colchicine + optimal medical therapy with Placebo + optimal medical therapy (2 arms). Primary endpoint: Major adverse cardiovascular event. Started Mar 2023; status: recruiting.
02
Drugs
colchicine
03
Conditions
atherosclerosisischemic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on ACTRN12621001408875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001408875.